Executive Summary

Children really are not little adults: What we can take away from the 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices

Antiplatelet therapy and anticoagulants

Letter to the Editor: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary.

Preface. 1. How to Use this Book. Introduction. The Text of the Chapters. What Should You Do if You Run into Trouble? Elephants. The Numerical Examples in the Text. Boxes. Executive Summaries. Why Go to All that Bother? The Bibliography. 2. Introduction. What are Statistics? Notation. Notation for Calculating the Mean. 3. Summarizing Variation. Introduction. Different Summaries of Variation. Why n - 1? Why the Squared Deviations? The Standard Deviation. The Next Chapter. 4. When are Sums of Squares Not Sums of Squares? Introduction. Calculating Machines Offer a Quicker Method of Calculating Sums of Avoid Being Confused by the Term of Squares. Summary of the Calculator Method of Calculating Down to Standard Deviation. 5. The Normal Distribution. Introduction. Frequency Distributions. The Normal Distribution. What Per Cent is a Standard Deviation Worth? Are the Percentages Always the Same as These? Other Similar Scales in Everyday Life. The Standard Deviation as an Estimate of the Frequency of a Number Occurring in a Sample. From Per Cent to Probability. Executive Summary 1 -The Standard Deviation. 6. The Relevance of the Normal Distribution to Biological Data. To Recap. Is Our Observed Distribution Normal? What Can We Do about a Distribution that Clearly is not Normal? How Many Samples are Needed? 7. Further Calculations from the Normal Distribution. Introduction. Is Bigger than B? The Yardstick for Deciding. Derivation of the Standard Error of a Difference Between Two Means. The Importance of the Standard Error of Differences Between Means. Summary of this Chapter. Executive Summary 2 - Standard Error of a Difference Between Two Means. 8. The t-test. Introduction. The Principle of the t-test. The t-test in Statistical Terms. Why t? Tables of the t-distribution. The Standard t-test. t-test for Means Associated with Unequal Variances. The Paired t-test. Executive Summary 3 - The t-test. 9. One Tail or Two? Introduction. Why is the Analysis of Variance F-test One-tailed? The Two-tailed F-test. How Many Tails has the t-test? The Final Conclusion on Number of Tails. 10. Analysis of Variance - What is it? How Does it work? Introduction. Sums of Squares in the Analysis of Variance. Some Made-up Variation to Analyze by Anova. The Sum of Squares Table. Using Anova to Sort Out the Variation in Table C. The Relationship Between t and F. Constraints on the Analysis of Variance. Comparison Between Treatment Means in the Analysis of Variance. The Least Significant Difference. A Caveat About Using the LSD. Executive Summary 4 - The Principle of the Analysis of Variance. 11. Experimental Designs for Analysis of Variance. Introduction. Fully Randomized. Randomized Blocks. Incomplete Blocks. Latin Square. Split Plot. Executive Summary 5 - Analysis of a Randomized Block Experiment. 12. Introduction to Factorial Experiments. What is a Factorial Experiment? Interaction. How Does a Factorial Experiment Change the Form of the Analysis of Variance? Sums of Squares for Interactions. 13. 2-Factor Factorial Experiments. Introduction. An Example of a 2-Factor Experiment. Analysis of the 2-Factor Experiment. Two Important Things to Remember About Factorials Before Tackling the Next Chapter. Analysis of Factorial Experiments with Unequal Replication. Executive Summary 6 - Analysis of a 2-Factor Randomized Block Experiment. 14. Factorial Experiments with More than Two Factors. Introduction. Different Orders of Interaction. Example of a 4-Factor Experiment. Addendum - Additional Working of Sum of Squares Calculations. 15. Factorial Experiments with Split Plots. Introduction. Deriving the Split Plot Design from the Randomized Block Design. Degrees of Freedom in a Split Plot Analysis. Numerical Example of a Split Plot Experiment and its Analysis. Comparison of Split Plot and Randomized Block Experiment. Uses of Split Plot Designs. 16. The t-test in the Analysis of Variance. Introduction. Brief Recap of Relevant Earlier Sections of this Book. Least Significant Difference Test. Multiple Range Tests. Testing Differences Between Means. Presentation of the Results of Tests of Differences Between Means. The Results of the Experiments Analyzed by Analysis of Variance in Chapters 11-15. 17. Linear Regression and Correlation. Introduction. Cause and Effect. Other Traps Waiting for You to Fall Into. Regression. Independent and Dependent Variables. The Regression Coefficient (b). Calculating the Regression Coefficient (b). The Regression Equation. A Worked Example on Some Real Data. Correlation. Extensions of Regression Analysis. Executive Summary 7 - Linear Regression. 18. Chi-square Tests. Introduction. When and Where Not to Use c2. The Problem of Low Frequencies. Yates' Correction for Continuity. The c 2 Test for Goodness of Fit. Association (or Contingency) c2. 19. Nonparametric Methods (What are They?). Disclaimer. Introduction. Advantages and Disadvantages of the Two Approaches. Some Ways Data are Organized for Nonparametric Tests. The Main Nonparametric Methods that are Available. Appendix. A1 How Many Replicates? A2 Statistical Tables. A3 Solutions to Spare-time Activities. A4 Bibliography. Index.

Correction to: 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Comparison of Additional Versus No Additional Heparin During Therapeutic Oral Anticoagulation in Patients Undergoing Percutaneous Coronary Intervention

The purpose of this report is to provide the Department of Energy Richland Operations Office (RL) a monthly summary of the Central Plateau Contractor's Environmental Management (EM) performance by Fluor Hanford (FH) and its subcontractors. Only current FH workscope responsibilities are described and other contractor/RL managed work is excluded. Please refer to other sections (BHI, PNNL) for other contractor information. Section A, Executive Summary, provides an executive level summary of the cost, schedule, and technical performance described in this report. It summarizes performance for the period covered, highlights areas worthy of management attention, and provides a forward look to some of the upcoming key performance activities as extracted from the contractor baseline. The remaining sections provide detailed performance data relative to each individual subproject (e.g., Plutonium Finishing Plant, Spent Nuclear Fuels, etc.), in support of Section A of the report. All information is updated as of the end of September 2002 unless otherwise noted. ''Stoplight?'' boxes are used to indicate at a glance the condition of a particular safety area. Green boxes denote either (1) the data are stable at a level representing ''acceptable'' performance, or (2) an improving trend exists. Yellows denote the data are stable at a levelmore » from which improvement is needed. Red denotes a trend exists in a non-improving direction.« less

The purpose of this report is to provide the Department of Energy Richland Operations Office (RL) a monthly summary of the Central Plateau Contractor's Environmental Management (EM) performance by Fluor Hanford (FH) and its subcontractors. Only current FH workscope responsibilities are described. Please refer to other sections (BHI, PNNL) for other contractor information. Section A, Executive Summary, provides an executive level summary of the cost, schedule, and technical performance described in this report. It summarizes performance for the period covered, highlights areas worthy of management attention, and provides a forward look to some of the upcoming key performance activities as extracted from the contractor baseline. The remaining sections provide detailed performance data relative to each individual subproject (e.g., Plutonium Finishing Plant, Spent Nuclear Fuels, etc.), in support of Section A of the report. All information is updated as of October 31, 2001 unless otherwise noted. ''Stoplight'' boxes are used to indicate at a glance the condition of a particular safety area. Green boxes denote either (1) the data are stable at a level representing ''acceptable'' performance, or (2) an improving trend exists. Yellows denote the data are stable at a level from which improvement is needed. Red denotes a trend exists in a non-improving direction.

The purpose of this report is to provide the Department of Energy Richland Operations Office (DOE-RL) a monthly summary of the Project Hanford Management Contractor's (PHMC) Environmental Management (EM) performance by Fluor Hanford (FH) and its subcontractors. In addition to project-specific information, it includes some PHMC-level data not detailed elsewhere in the report. Section A, Executive Summary, provides an executive level summary of the cost, schedule, and technical performance described in this report. It summarizes performance for the period covered, highlights areas worthy of management attention, and provides a forward look to some of the upcoming key performance activities as extracted from the PHMC baseline. The remaining sections provide detailed performance data relative to each individual Project (e.g., Waste Management, Spent Nuclear Fuels, etc.), in support of Section A of the report. Unless otherwise noted, the Safety, Conduct of Operations, and Cost/Schedule data contained herein is as of January 31, 2001. All other information is updated as of February 20, 2001 unless otherwise noted. ''Stoplight'' boxes are used to indicate at a glance the condition of a particular area. Green boxes denote on schedule. Yellows denote behind schedule but recoverable. Red is either missed or unrecoverable.

This section provides an executive level summary of the performance information covered in this report and is intended to bring to Management's attention that information considered to be most noteworthy. All cost, schedule, milestone commitments, performance measures. and safety data is current as of August 31. Accomplishments, Issues and Integration items are current as of September 18 unless otherwise noted. The section begins with a description of notable accomplishments that have occurred since the last report and are considered to have made the greatest contribution toward safe, timely, and cost-effective clean up. Following the accomplishment section is an overall fiscal year-to-date summary analysis addressing cost, schedule, and milestone performance. Overviews of safety ensue. The next segment of the Executive Summary, entitled Critical Issues, is designed to identify the high-level challenges to achieving cleanup progress. The next section includes FY 2000 EM Management Commitment High Visibility Project Milestones and Critical Few Performance Measures. The Key Integration Activities section follows next, highlighting PHMC activities that cross contractor boundaries and demonstrate the shared value of partnering with other Site entities to accomplish the work. Concluding the Executive Summary, a forward-looking synopsis of Upcoming Planned Key Events is provided.

Chlorthalidone or Hydrochlorothiazide for Treatment of Hypertension

The purpose of this report is to provide the Department of Energy Richland Operations Office (DOE-RL) a monthly summary of the Project Hanford Management Contractor's (PHMC) Environmental Management (EM) performance by Fluor Hanford (FH) and its subcontractors. In addition to project-specific information, it includes some PHMC-level data not detailed elsewhere in the report. Section A, Executive Summary, provides an executive level summary of the cost, schedule, and technical performance described in this report. It summarizes performance for the period covered, highlights areas worthy of management attention, and provides a forward look to some of the upcoming key performance activities as extracted from the PHMC baseline. The remaining sections provide detailed performance data relative to each individual Project (e.g., Waste Management, Spent Nuclear Fuels, etc.), in support of Section A of the report. Unless otherwise noted, the Safety, Conduct of Operations, and Cost/Schedule data contained herein is as of July 31, 2000. All other information is updated as of August 24, unless otherwise noted. ''Stoplight'' boxes are used to indicate at a glance the condition of a particular area. Green boxes denote on schedule. Yellows denote behind schedule but recoverable. Red is either missed or unrecoverable.

The purpose of this report is to provide the Department of Energy Richland Operations Office (DOE-RL) a monthly summary of the Project Hanford Management Contractor's (PHMC) Environmental Management (EM) performance by Fluor Hanford (FH) and its subcontractors. In addition to project-specific information, it includes some PHMC-level data not detailed elsewhere in the report. Section A, Executive Summary, provides an executive level summary of the cost, schedule, and technical performance described in this report. It summarizes performance for the period covered, highlights areas worthy of management attention, and provides a forward look to some of the upcoming key performance activities as extracted from the PHMC baseline. The remaining sections provide detailed performance data relative to each individual Project (e.g., Waste Management, Spent Nuclear Fuels, etc.), in support of Section A of the report. Unless otherwise noted, the Safety, Conduct of Operations, and Cost/Schedule data contained herein is as of April 30, 2000. All other information is updated as of May 19, unless otherwise noted.

HomeCirculationVol. 102, No. 14Correction ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) Originally published3 Oct 2000https://doi.org/10.1161/01.CIR.102.14.1739Circulation. 2000;102:1739This article corrects the followingACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations An incorrect sentence (The present guidelines supersede the 1994 guidelines.) on the first page of the guidelines (Circulation. 2000;102:1193–1209.) was printed. We regret the error and provide the correct text below in brackets.This Task Force therefore formed the current committee to develop guidelines for the management of unstable angina and non–ST-segment elevation myocardial infarction, [supported by the Agency for Healthcare Research and Quality’s UCSF-Stanford Evidence-Based Practice Center. This document will serve as a useful successor to the 1994 AHCPR guidelines.]Additionally, information regarding endorsement of the guidelines was omitted from publication. These guidelines have been officially endorsed by the American College of Emergency Physicians (ACEP)* and the Society for Cardiac Angiography and Interventions. 1Endorsement by ACEP means that ACEP agrees with the general concepts in the guidelines and believes that the developers have begun to define a process of care that considers the best interests of patients with unstable angina and non–ST-segment elevation myocardial infarction. Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yankovetska A, Vernyhorodskyi S, Paliy I and Zaika S (2021) MORPHOLOGICAL CHANGES OF THE GASTRIC MUCOSA WHILE USING ANTIAGGREGANTS AND PANTOPRAZOLE (AN EXPERIMENTAL STUDY), Wiadomości Lekarskie, 10.36740/WLek202102110, 74:2, (228-235), Online publication date: 1-Feb-2021. Li Q, Chen Q, Zhang H, Xu Z, Wang X, Pang J, Ma J, Ling W and Li D (2020) Associations of serum magnesium levels and calcium–magnesium ratios with mortality in patients with coronary artery disease, Diabetes & Metabolism, 10.1016/j.diabet.2019.12.003, 46:5, (384-391), Online publication date: 1-Oct-2020. Parkhomenko A, Lutay Y, Dosenko V, Gurianova V, Moibenko A and Skarzevskiy A (2010) Influence of endothelial nitric oxide synthase T-786→C-promoter polymorphism on integral parameters of functional condition of arterial vessels, Fiziolohichnyĭ zhurnal, 10.15407/fz56.01.022, 56:1, (22-29), Online publication date: 2-Feb-2010. DAIDA H (2003) Acute coronary syndrome--Diagnosis, and treatment--急性冠症候群の診断と治療, Juntendo Medical Journal, 10.14789/pjmj.48.448, 48:4, (448-457), . Choi A, Kim M, Sung J, Kim S, Lee J, Hyun H, Kim J and Chang H (2021) Development of Prediction Models for Acute Myocardial Infarction at Prehospital Stage with Machine Learning Based on a Nationwide Database (Preprint), JMIR Medical Informatics, 10.2196/27405 Aldalati A, Bellamkonda V, Moore G and Finch A (2021) Three Cases of Emergency Department Medical Malpractice Involving “Consultations”: How Is Liability Legally Determined?, Clinical Practice and Cases in Emergency Medicine, 10.5811/cpcem.2021.7.52680, 5:3, (283-288) Related articlesACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations Eugene Braunwald, et al. Circulation. 2000;102:1193-1209 October 3, 2000Vol 102, Issue 14 Advertisement Article InformationMetrics Copyright © 2000 by American Heart Associationhttps://doi.org/10.1161/01.CIR.102.14.1739 Originally publishedOctober 3, 2000 PDF download Advertisement

BACKGROUND: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR-RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR-RS-2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence-based findings of the document. ICAR-RS presents over 180 topics in the forms of evidence-based reviews with recommendations (EBRRs), evidence-based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. ICAR-RS-2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence-based management algorithm is provided. This ICAR-RS-2021 executive summary provides a compilation of the evidence-based recommendations for medical and surgical treatment of the most common forms of RS.